Centralized HIV-1 envelope immunogens and neutralizing antibodies - PubMed

Review

Centralized HIV-1 envelope immunogens and neutralizing antibodies

Feng Gao et al. Curr HIV Res. 2007 Nov.

Abstract

Centralized HIV-1 genes (consensus, most recent common ancestor and center of the tree) have recently been explored for induction of broadly reactive immune responses to overcome the extraordinary genetic diversity among HIV-1 strains. Although all of these strategies are based on artificial sequences predicted by computer programs, they retain biological function, and use the CCR5 co-receptor for entry into target cells as transmitted HIV-1 Envs. Results from laboratory animals indicate that centralized immunogens are superior to many wild-type immunogens for inducing cross-subtype T and B cell immune responses. Structural modifications have improved the ability of consensus Envs to elicit antibody responses that neutralize a spectrum of HIV-1 Env pseudoviruses. However, the more difficult to neutralize tier 2 Env pseudoviruses are generally not neutralized well by anti-consensus Env antibodies, indicating the need for further modifications, new formulations, or additional strategies to generate antibodies that neutralize a full spectrum of transmitted HIV-1 strains.

Similar articles

• Comparison of Immunogenicity in Rhesus Macaques of Transmitted-Founder, HIV-1 Group M Consensus, and Trivalent Mosaic Envelope Vaccines Formulated as a DNA Prime, NYVAC, and Envelope Protein Boost.

  Hulot SL, Korber B, Giorgi EE, Vandergrift N, Saunders KO, Balachandran H, Mach LV, Lifton MA, Pantaleo G, Tartaglia J, Phogat S, Jacobs B, Kibler K, Perdiguero B, Gomez CE, Esteban M, Rosati M, Felber BK, Pavlakis GN, Parks R, Lloyd K, Sutherland L, Scearce R, Letvin NL, Seaman MS, Alam SM, Montefiori D, Liao HX, Haynes BF, Santra S. Hulot SL, et al. J Virol. 2015 Jun;89(12):6462-80. doi: 10.1128/JVI.00383-15. Epub 2015 Apr 8. J Virol. 2015. PMID: 25855741 Free PMC article.

• Antigenicity and immunogenicity of HIV-1 consensus subtype B envelope glycoproteins.

  Kothe DL, Decker JM, Li Y, Weng Z, Bibollet-Ruche F, Zammit KP, Salazar MG, Chen Y, Salazar-Gonzalez JF, Moldoveanu Z, Mestecky J, Gao F, Haynes BF, Shaw GM, Muldoon M, Korber BT, Hahn BH. Kothe DL, et al. Virology. 2007 Mar 30;360(1):218-34. doi: 10.1016/j.virol.2006.10.017. Epub 2006 Nov 13. Virology. 2007. PMID: 17097711 Free PMC article.

• Antigenicity and immunogenicity of transmitted/founder, consensus, and chronic envelope glycoproteins of human immunodeficiency virus type 1.

  Liao HX, Tsao CY, Alam SM, Muldoon M, Vandergrift N, Ma BJ, Lu X, Sutherland LL, Scearce RM, Bowman C, Parks R, Chen H, Blinn JH, Lapedes A, Watson S, Xia SM, Foulger A, Hahn BH, Shaw GM, Swanstrom R, Montefiori DC, Gao F, Haynes BF, Korber B. Liao HX, et al. J Virol. 2013 Apr;87(8):4185-201. doi: 10.1128/JVI.02297-12. Epub 2013 Jan 30. J Virol. 2013. PMID: 23365441 Free PMC article.

• Centralized immunogens as a vaccine strategy to overcome HIV-1 diversity.

  Gao F, Korber BT, Weaver E, Liao HX, Hahn BH, Haynes BF. Gao F, et al. Expert Rev Vaccines. 2004 Aug;3(4 Suppl):S161-8. doi: 10.1586/14760584.3.4.s161. Expert Rev Vaccines. 2004. PMID: 15285714 Review.

• HIV-1 envelope glycoprotein immunogens to induce broadly neutralizing antibodies.

  Sliepen K, Sanders RW. Sliepen K, et al. Expert Rev Vaccines. 2016;15(3):349-65. doi: 10.1586/14760584.2016.1129905. Epub 2016 Jan 8. Expert Rev Vaccines. 2016. PMID: 26654478 Review.

Cited by

• Comparative Analysis of the Glycosylation Profiles of Membrane-Anchored HIV-1 Envelope Glycoprotein Trimers and Soluble gp140.

  Go EP, Herschhorn A, Gu C, Castillo-Menendez L, Zhang S, Mao Y, Chen H, Ding H, Wakefield JK, Hua D, Liao HX, Kappes JC, Sodroski J, Desaire H. Go EP, et al. J Virol. 2015 Aug;89(16):8245-57. doi: 10.1128/JVI.00628-15. Epub 2015 May 27. J Virol. 2015. PMID: 26018173 Free PMC article.

• Protective efficacy of centralized and polyvalent envelope immunogens in an attenuated equine lentivirus vaccine.

  Craigo JK, Ezzelarab C, Cook SJ, Liu C, Horohov D, Issel CJ, Montelaro RC. Craigo JK, et al. PLoS Pathog. 2015 Jan 8;11(1):e1004610. doi: 10.1371/journal.ppat.1004610. eCollection 2015 Jan. PLoS Pathog. 2015. PMID: 25569288 Free PMC article.

• Heterologous prime-boost-boost immunisation of Chinese cynomolgus macaques using DNA and recombinant poxvirus vectors expressing HIV-1 virus-like particles.

  Bridge SH, Sharpe SA, Dennis MJ, Dowall SD, Getty B, Anson DS, Skinner MA, Stewart JP, Blanchard TJ. Bridge SH, et al. Virol J. 2011 Sep 7;8:429. doi: 10.1186/1743-422X-8-429. Virol J. 2011. PMID: 21899739 Free PMC article.

• Critical issues in mucosal immunity for HIV-1 vaccine development.

  Haynes BF, Shattock RJ. Haynes BF, et al. J Allergy Clin Immunol. 2008 Jul;122(1):3-9; quiz 10-1. doi: 10.1016/j.jaci.2008.03.036. Epub 2008 May 12. J Allergy Clin Immunol. 2008. PMID: 18468671 Free PMC article. Review.

Publication types

MeSH terms

Substances

Grants and funding

LinkOut - more resources

• Full Text Sources

  • Bentham Science Publishers Ltd.
  • Ingenta plc
  • Ovid Technologies, Inc.

• Other Literature Sources

  • The Lens - Patent Citations Database